Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance and Accelerates Recurring Revenue Growth Across AI and Dermatology
Cosmo Pharmaceuticals (OTC:CMOPF), a leader in AI-powered healthcare and specialty pharma, reported strong H1 2025 results and raised its EBITDA guidance by 鈧�4.5 million. The company achieved total revenues of 鈧�51.7 million, including 鈧�41.9 million in recurring revenues.
Key growth drivers include GI Genius鈩� recurring revenues up 128% YoY and Winlevi庐 recurring revenues up 23% YoY. The company maintains a strong financial position with 鈧�133.3 million in cash and investments. Updated FY2025 guidance projects total revenues of 鈧�102-107 million and EBITDA of 鈧�5.5-7.5 million.
Operating expenses were controlled with R&D at 鈧�18.0 million (-6% YoY) and SG&A at 鈧�14.3 million (-13% YoY). The company operates across four strategic platforms: AI-powered MedTech, Dermatology, GI innovation, and CDMO services.
Cosmo Pharmaceuticals (OTC:CMOPF), leader nell'assistenza sanitaria potenziata dall'IA e nella farmaceutica specialistica, ha riportato solidi risultati nel primo semestre 2025 e ha aumentato la guidance sull'EBITDA di 4,5 milioni di euro. L'azienda ha raggiunto ricavi totali per 51,7 milioni di euro, di cui 41,9 milioni di euro da ricavi ricorrenti.
I principali motori di crescita includono ricavi ricorrenti di GI Genius鈩� in aumento del 128% su base annua e ricavi ricorrenti di Winlevi庐 in crescita del 23% su base annua. L'azienda mantiene una solida posizione finanziaria con 133,3 milioni di euro in liquidit脿 e investimenti. La guidance aggiornata per l'intero 2025 prevede ricavi totali tra 102 e 107 milioni di euro e un EBITDA compreso tra 5,5 e 7,5 milioni di euro.
Le spese operative sono state contenute, con R&S a 18,0 milioni di euro (-6% su base annua) e SG&A a 14,3 milioni di euro (-13% su base annua). L'azienda opera su quattro piattaforme strategiche: MedTech potenziata dall'IA, Dermatologia, innovazione gastrointestinale e servizi CDMO.
Cosmo Pharmaceuticals (OTC:CMOPF), l铆der en salud impulsada por IA y farmac茅utica especializada, report贸 s贸lidos resultados en el primer semestre de 2025 y elev贸 su gu铆a de EBITDA en 4,5 millones de euros. La compa帽铆a alcanz贸 ingresos totales de 51,7 millones de euros, incluyendo 41,9 millones de euros en ingresos recurrentes.
Los principales impulsores de crecimiento incluyen ingresos recurrentes de GI Genius鈩� con un aumento del 128% interanual y ingresos recurrentes de Winlevi庐 con un crecimiento del 23% interanual. La empresa mantiene una s贸lida posici贸n financiera con 133,3 millones de euros en efectivo e inversiones. La gu铆a actualizada para todo 2025 proyecta ingresos totales de 102-107 millones de euros y un EBITDA de 5,5-7,5 millones de euros.
Los gastos operativos se controlaron con I+D en 18,0 millones de euros (-6% interanual) y SG&A en 14,3 millones de euros (-13% interanual). La empresa opera en cuatro plataformas estrat茅gicas: MedTech impulsada por IA, Dermatolog铆a, innovaci贸n gastrointestinal y servicios CDMO.
Cosmo Pharmaceuticals (OTC:CMOPF)電� AI 旮半皹 項姢旒�鞏� 氚� 鞝勲 鞝滌暯 攵勳暭鞚� 靹犽憪欤检瀽搿滌劀 2025雲� 靸侂皹旮� 臧曤牓頃� 鞁れ爜鞚� 氤搓碃頃橁碃 EBITDA 臧�鞚措崢鞀るゼ 450毵� 鞙犽 靸來枼 臁办爼頄堨姷雼堧嫟. 須岇偓電� 齑� 毵れ稖 5,170毵� 鞙犽毳� 雼劚頄堨溂氅�, 鞚� 欷� 41.9氚彪 鞙犽電� 氚橂车 毵れ稖鞛呺媹雼�.
欤检殧 靹膘灔 霃欕牓鞙茧電� GI Genius鈩� 氚橂车 毵れ稖鞚� 鞝勲厔 雽�牍� 128% 歃濌皜顷橁碃, Winlevi庐 氚橂车 毵れ稖鞚� 鞝勲厔 雽�牍� 23% 歃濌皜頃� 鞝愳澊 鞛堨姷雼堧嫟. 須岇偓電� 1鞏� 3,330毵� 鞙犽鞚� 順勱笀 氚� 韴瀽 鞛愳偘鞚� 氤挫湢頃橂┌ 瓴碃頃� 鞛 靸來儨毳� 鞙犾頃橁碃 鞛堨姷雼堧嫟. 2025雲� 鞝勳泊 臧�鞚措崢鞀る姅 齑� 毵れ稖鞚� 1鞏� 2氚彪~1鞏� 700毵� 鞙犽, EBITDA毳� 550毵寏750毵� 鞙犽搿� 鞓堨儊頃╇媹雼�.
鞖挫榿牍勳毄鞚� 鞐瓣惮臧滊皽牍勱皜 1,800毵� 鞙犽(-6% 鞝勲厔 雽�牍�), 韺愲Г甏�毽箘臧� 1,430毵� 鞙犽(-13% 鞝勲厔 雽�牍�)搿� 韱奠牅霅橃棃鞀惦媹雼�. 須岇偓電� AI 旮半皹 鞚橂旮办垹, 頂茧秬瓿�, 鞙勳灔甏� 順侅嫚, CDMO 靹滊箘鞀� 霌� 雱� 臧�歆� 鞝勲灥鞝� 頂岆灚韽检棎靹� 靷梾鞚� 鞖挫榿頃橁碃 鞛堨姷雼堧嫟.
Cosmo Pharmaceuticals (OTC:CMOPF), un leader dans le domaine de la sant茅 assist茅e par IA et de la pharma sp茅cialis茅e, a annonc茅 de solides r茅sultats pour le premier semestre 2025 et a relev茅 ses pr茅visions d'EBITDA de 4,5 millions d'euros. La soci茅t茅 a r茅alis茅 un chiffre d'affaires total de 51,7 millions d'euros, dont 41,9 millions d'euros de revenus r茅currents.
Les principaux moteurs de croissance incluent une augmentation de 128 % des revenus r茅currents de GI Genius鈩� en glissement annuel et une hausse de 23 % des revenus r茅currents de Winlevi庐 en glissement annuel. L'entreprise conserve une solide position financi猫re avec 133,3 millions d'euros en liquidit茅s et investissements. Les pr茅visions mises 脿 jour pour l'exercice 2025 projettent un chiffre d'affaires total de 102 脿 107 millions d'euros et un EBITDA compris entre 5,5 et 7,5 millions d'euros.
Les d茅penses op茅rationnelles ont 茅t茅 ma卯tris茅es avec la R&D 脿 18,0 millions d'euros (-6 % en glissement annuel) et les SG&A 脿 14,3 millions d'euros (-13 % en glissement annuel). La soci茅t茅 op猫re sur quatre plateformes strat茅giques : MedTech assist茅e par IA, dermatologie, innovation gastro-intestinale et services CDMO.
Cosmo Pharmaceuticals (OTC:CMOPF), ein f眉hrendes Unternehmen im Bereich KI-gest眉tzte Gesundheitsversorgung und Spezialpharma, meldete starke Ergebnisse f眉r das erste Halbjahr 2025 und hob seine EBITDA-Prognose um 4,5 Millionen Euro an. Das Unternehmen erzielte Gesamtums盲tze von 51,7 Millionen Euro, davon 41,9 Millionen Euro aus wiederkehrenden Ums盲tzen.
Wichtige Wachstumstreiber sind GI Genius鈩� wiederkehrende Ums盲tze mit einem Anstieg von 128 % gegen眉ber dem Vorjahr und Winlevi庐 wiederkehrende Ums盲tze mit einem Wachstum von 23 % gegen眉ber dem Vorjahr. Das Unternehmen verf眉gt 眉ber eine starke Finanzlage mit 133,3 Millionen Euro an liquiden Mitteln und Investitionen. Die aktualisierte Prognose f眉r das Gesamtjahr 2025 erwartet Gesamtums盲tze von 102-107 Millionen Euro und ein EBITDA von 5,5-7,5 Millionen Euro.
Die Betriebskosten wurden kontrolliert, mit F&E bei 18,0 Millionen Euro (-6 % gegen眉ber dem Vorjahr) und SG&A bei 14,3 Millionen Euro (-13 % gegen眉ber dem Vorjahr). Das Unternehmen ist in vier strategischen Plattformen t盲tig: KI-gest眉tzte MedTech, Dermatologie, Innovation im Gastrointestinalbereich und CDMO-Dienstleistungen.
- EBITDA guidance raised by 鈧�4.5 million for FY2025
- GI Genius鈩� recurring revenues grew 128% year-over-year
- Winlevi庐 recurring revenues increased 23% year-over-year
- Strong cash position of 鈧�133.3 million as of June 30, 2025
- Reduced operating expenses with R&D down 6% and SG&A down 13% YoY
- Healthy equity ratio of 75.4%
- Operating loss of 鈧�1.41 million in H1 2025 compared to 鈧�78.7 million profit in H1 2024
- Net loss of 鈧�2.03 million versus 鈧�71.2 million profit in H1 2024
- Total revenues declined to 鈧�51.7 million from 鈧�136.2 million in H1 2024
- Cost of sales increased 10% year-over-year to 鈧�25.6 million
Ad hoc announcement pursuant to Art. 53 LR
EBITDA guidance raised by €4.5M as Cosmo executes on its Vision 2030 strategy; H1 Recurring Revenues from GI Genius™ up
Dublin, Ireland--(Newsfile Corp. - July 23, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today reported strong half-year results for 2025, underscoring the Company’s strategic execution, commercial momentum, and capital discipline across its key growth platforms.
On the back of robust performance in H1 2025, Cosmo has raised its full-year EBITDA guidance by €4.5 million and reconfirmed its total revenue outlook for 2025, while confirming double-digit growth in recurring revenues – driven by its leading products and technologies in MedTech AI and Dermatology.
Updated Full-Year 2025 Guidance
- Total Revenues: €102–107 million
-
- ~€17 million in project-based revenues
- €85–90 million in recurring revenues
- EBITDA: €5.5–7.5 million, raised from previous guidance due to higher-than-expected other income and improved operational efficiencies
- Cash, Equivalents & Investments: Expected to remain above €110 million
H1 2025 Highlights
Cosmo delivered strong financial and operational performance in the first half of 2025, with strong momentum in GI Genius™ and Winlevi®, continued cost discipline, and a strong balance sheet.
- Total Revenues: €51.7 million
-
- €41.9 million in recurring revenues
- €9.8 million in project-based revenues
- Growth Drivers:
- GI Genius™ recurring revenues: +
128% YoY - Winlevi® recurring revenues: +
23% YoY
- GI Genius™ recurring revenues: +
- Operating Expenses: €57.8 million
- Cost of Sales: €25.6 million (+
10% YoY) - R&D: €18.0 million (–
6% YoY) - SG&A: €14.3 million (–
13% YoY)
- Cost of Sales: €25.6 million (+
- Cash, Equivalents, and Investments: €133.3 million as of June 30, 2025
- Treasury Shares: 1.6 million shares held as of June 30, 2025 (~€97.7 million), an increase of 76.2K shares vs. December 31, 2024
H2 2025 Outlook
Cosmo expects continued momentum in the second half of 2025, with:
- Recurring revenues: €43 – 48 million
- Continued triple digit growth from GI Genius®, double digit growth from Winlevi® and steady growth from Gastro and CDMO business.
- Increased R&D spending to advance Phase II programs for Bile Acid Diarrhoea and Distal Ulcerative Colitis.
- Continued SG&A discipline to drive margin expansion
Strategic Context
Cosmo operates at the intersection of high-growth global markets — AI in endoscopy, Dermatology, Gastrointestinal diseases, and advanced Drug Manufacturing.
Each of these sectors is fuelled by large, persistent clinical unmet needs:
- In MedTech AI, Cosmo’s GI Genius™ is redefining detection and diagnostic accuracy in real time.
- In Dermatology, Winlevi® is the first new acne mechanism of action in decades.
- In Gastroenterology, Cosmo’s Phase II pipeline addresses conditions like Bile Acid Diarrhoea and distal ulcerative colitis.
- In CDMO, Cosmo supports global pharmaceutical partners with advanced formulation, regulatory, and sterile manufacturing expertise.
What makes Cosmo unique is its ability to scale innovation across all four businesses — leveraging common R&D infrastructure, regulatory know-how, Artificial Intelligence, Digital capabilities, and manufacturing excellence. This integrated model is designed to unlock operational leverage, reduce time-to-market, and drive compounding long-term growth.
Giovanni Di Napoli, Chief Executive Officer of Cosmo, commented:
“These results validate our strategy: we are scaling impact across high-need therapeutic areas with real momentum. What sets Cosmo apart is our ability to operate as one company with four powerful platforms: AI-powered MedTech, next-generation Dermatology, GI innovation, and high-value CDMO. These aren’t isolated businesses, they reinforce each other, creating a scalable ecosystem with clinical, operational, and financial synergies. We’re not just growing — we’re compounding. And this is just the beginning of our 2030 vision.”
Svetlana Sigalova, Chief Financial Officer of Cosmo, added:
“Our first-half results reflect strong execution, continued growth in recurring revenues, and prudent financial management. We remain disciplined in controlling costs and investing where it matters most. With a solid balance sheet and clear capital priorities, we’re well positioned to support Cosmo’s long-term growth and deliver on our 2030 ambition.”
Analyst, media and investors call today at 2 pm CET
Cosmo invites investors, financial analysts and business/life sciences journalists to a live webcast presentation which will follow today at 2:00 pm CET.
To join via Web browser, click
To join via phone, please use one of the following dial-in numbers:
- Switzerland/Europe +41 (0) 58 310 50 00
- United Kingdom +44 (0) 207 107 06 13
- United States +1 (1) 631 570 56 13
Key figures
| EUR 1’000 | H1 2025 | H1 2024 |
| Income statement | ||
| Revenue | 51,720 | 136,237 |
| Recurring Revenues | 41,925 | 42,379 |
| Project Based Revenues | 9,795 | 93,858[1] |
| Cost of sales | (25,571) | (23,150) |
| Gross profit | 26,149 | 113,087 |
| Other income | 4,701 | 1,122 |
| R&D costs | (17,997) | (19,137) |
| SG&A costs | (14,264) | (16,323) |
| Net operating expenses | (27,560) | (34,338) |
| Operating profit/(loss) | (1,411) | 78,749 |
| Net financial income | 741 | 1,794 |
| Profit/(loss) before taxes | (670) | 80,543 |
| Profit/(loss) after taxes for the period | (2,030) | 71,177 |
| EBITDA | 4,852 | 84,868 |
| Statement of financial position | As of 30 June 2025 | As of 31 December 2024 |
| Non-current assets | 423,104 | 444,514 |
| Cash and cash equivalents | 50,749 | 44,296 |
| Other current assets | 136,477 | 157,962 |
| Liabilities | 143,354 | 141,681 |
| Equity attributable to owners of the Company | 460,239 | 498,330 |
| Non-controlling interests | 6,737 | 6,761 |
| Equity ratio (%) | | |
| Shares | H1 2025 | H1 2024 |
| Weighted average number of shares | 15,970,541 | 16,105,126 |
| Earnings/(loss) per share (in EUR) | (0.126) | 4.423 |
The full Half-Year 2025 Report of Cosmo can be found for download as pdf-document on the Company’s website via
About Cosmo
Cosmo is a life sciences company focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). We design, develop, and manufacture advanced solutions that address critical medical needs and raise the standard of care. Our technologies are trusted by leading global pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. Guided by our purpose - Building Health Confidence - our mission is to empower patients, healthcare professionals, and partners by innovating at the intersection of science and technology. Founded in 1997, Cosmo is headquartered in Dublin, Ireland, with offices in San Diego (USA), and in Lainate, Rome, and Catania (Italy). For more information, visit
Financial calendar
| H.C. Wainwright 27th Annual Global Investment Conference, New York City, USA | September 8-10, 2025 |
For further information, please contact:
[1] H1 2024 Project Based revenues include €92.5 million milestone from Medtronic
Attachments
To view the source version of this press release, please visit
FAQ
What are Cosmo's (CMOPF) updated financial guidance numbers for 2025?
How did Cosmo's GI Genius and Winlevi products perform in H1 2025?
What was Cosmo's financial position as of June 30, 2025?
How did Cosmo's operating expenses change in H1 2025?
What are the main business segments of Cosmo Pharmaceuticals?
